Open AccessExenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial
Author(s) -
Luba Yammine,
Charles E. Green,
Thomas R. Kosten,
Constanza de Dios,
Robert Suchting,
Scott D. Lane,
Christopher D. Verrico,
Joy M. Schmitz
Publication year - 2021
Publication title -
nicotine and tobacco research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.338
H-Index - 113
eISSN - 1469-994X
pISSN - 1462-2203
DOI - 10.1093/ntr/ntab066
Subject(s) - smoking cessation , adjunct , randomized controlled trial , medicine , nicotine patch , nicotine replacement therapy , weight gain , nicotine , physical therapy , psychiatry , body weight , alternative medicine , placebo , pathology , philosophy , linguistics
Approved pharmacological treatments for smoking cessation are modestly effective, underscoring the need for improved pharmacotherapies. Glucagon-like peptide-1 receptor (GLP-1R) agonists attenuate the rewarding effects of nicotine in preclinical studies. We examined the efficacy of extended-release exenatide, a GLP-1R agonist, combined with nicotine replacement therapy (NRT, patch) for smoking cessation, craving, and withdrawal symptoms, with post-cessation body weight as a secondary outcome.